רגולקס Israel - ebraică - Ministry of Health

רגולקס

neopharm consumer products ltd, israel - polyethylene glycol 3350 - אבקה להכנת תרחיף - polyethylene glycol 3350 99.973 %w/w - macrogol - macrogol - treatment of constipation.

בלנאום פלוס Israel - ebraică - Ministry of Health

בלנאום פלוס

neopharm ltd - polidocanol; soya oil - תמיסה - soya oil 82.95 g / 100 g; polidocanol 15 g / 100 g - polidocanol - polidocanol - refatting medical oil bath with antipruritic effect.

אקנהמיצין Israel - ebraică - Ministry of Health

אקנהמיצין

neopharm ltd - erythromycin - תמיסה - חיצוני - erythromycin 2 % - erythromycin - erythromycin - all forms of acne, particularly inflammatory forms with papules and pustules.

אקנהמיצין פלוס Israel - ebraică - Ministry of Health

אקנהמיצין פלוס

neopharm ltd - erythromycin; tretinoin - תמיסה - erythromycin 4 g / 100 g; tretinoin 0.025 g / 100 g - erythromycin, combinations - erythromycin, combinations - all forms of acne, both non-inflammatory forms with comedones and inflammatory forms with papules and pustules, particularly in the case of fat-rich skin.

רבלימיד 5 מג Israel - ebraică - Ministry of Health

רבלימיד 5 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 5 מג Israel - ebraică - Ministry of Health

רבלימיד 5 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 10 מג Israel - ebraică - Ministry of Health

רבלימיד 10 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 10 מג Israel - ebraică - Ministry of Health

רבלימיד 10 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 15 מג Israel - ebraică - Ministry of Health

רבלימיד 15 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 15 מג Israel - ebraică - Ministry of Health

רבלימיד 15 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.